Global private equity giant Bain Capital is set to divest its remaining stake in Emcure Pharmaceuticals through a block deal. This move is expected to fetch around ₹1,700 crore ($200 million), marking the latest development in Bain’s decade-long investment in the Indian pharmaceutical company.
Bain Capital first acquired its stake in Emcure in 2013, purchasing it from Blackstone Group for ₹700 crore. When Emcure went public in February 2024, Bain took the opportunity to sell a portion of its holdings. As of December 2024, Bain still holds 8.68% (approximately 16.5 million shares) in Emcure through its investment arm, BC Investments IV Ltd.
With the mandatory lock-in period for post-IPO investors now over, Bain Capital is moving ahead with its complete exit from Emcure. The block deal will be executed with the assistance of Kotak Mahindra Capital Co., which has been appointed as the financial advisor for the transaction.
On the day of the announcement, Emcure’s stock closed at ₹1,075 per share, reflecting a 2.45% increase. The company’s total market capitalization stood at ₹20,363.92 crore. Meanwhile, broader market trends showed a decline, with the Nifty Pharma index down by 0.65% and the Nifty 50 index falling by 0.31%.
This planned exit allows the firm to realize gains on its initial investment. The firm had invested ₹700 crore in Emcure and is now set to exit at a much higher valuation. The transaction will also provide liquidity in the stock, potentially attracting new institutional investors.